m6A-Methylated NUTM2B-AS1 Promotes Hepatocellular Carcinoma Stemness Feature via Epigenetically Activating BMPR1A Transcription DOI Creative Commons
Wenchuan Li,

Min Zeng,

Yuanjia Ning

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 2393 - 2411

Published: Dec. 1, 2024

Purpose: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in world. Oncofetal proteins are optimal diagnostic biomarkers and therapeutic targets for HCC. As abundant modification RNA, N 6 -methyladenosine (m A) has been reported to be involved HCC initiation progression. However, whether m A oncofetal characteristics remains unknown. Methods: Gene expression tissues cells was detected using qPCR. The level methylation determined methylated RNA immunoprecipitation assay. biological roles NUTM2B-AS1 were Cell Counting Kit-8, 5-ethynyl-2'-deoxyuridine incorporation, spheroid formation assays. mechanisms underlying explored (RIP), chromatin isolation by purification (ChIRP), (ChIP), assay transposase-accessible (ATAC). Results: identified as a novel long noncoding that upregulated fetal liver silenced adult tissues. METTL3 METTL16 induce hypermethylation NUTM2B-AS1. levels exhibit characteristics. upregulates increasing transcript stability. A-methylated promotes cell proliferation stemness via epigenetically activating BMPR1A expression. specifically binds promoter. recognized reader YTHDC2, which further H3K4 methyltransferase MLL1. recruits YTHDC2 MLL1 promoter, leading increased H3K4me3 accessibility at Functional rescue assays suggest critical mediator oncogenic role Conclusion: METTL3- METTL16-mediated molecular event transcription. Keywords: -methyladenosine, molecule, hepatocellular carcinoma, stemness, histone

Language: Английский

Crosstalk between m6A modification and non-coding RNAs in HCC DOI

Zitong Qiu,

Xingxing Yuan, Xinyue Wang

et al.

Cellular Signalling, Journal Year: 2024, Volume and Issue: 117, P. 111076 - 111076

Published: Feb. 2, 2024

Language: Английский

Citations

7
The epigenetic regulatory network of long noncoding RNAs in hepatocellular carcinoma DOI Creative Commons

Zhaoqi Shi,

Shengxi Jin, Xiaolong Liu

et al.

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101534 - 101534

Published: Jan. 1, 2025

Language: Английский

Citations

0
Emerging importance of m6A modification in liver cancer and its potential therapeutic role DOI
Tao Chen,

Wufei Ye,

Songsen Gao

et al.

Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, Journal Year: 2025, Volume and Issue: unknown, P. 189299 - 189299

Published: March 1, 2025

Language: Английский

Citations

0
Research Progress on the Role of Epigenetic Methylation Modification in Hepatocellular Carcinoma DOI Creative Commons
J Wang,

Wenyue Gao,

Hongbo Yu

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 1143 - 1156

Published: June 1, 2024

Abstract: Hepatocellular carcinoma (HCC) stands as the prevailing form of primary liver cancer, characterized by a poor prognosis and high mortality rate. A pivotal factor in HCC tumorigenesis is epigenetics, specifically regulation gene expression through methylation. This process relies significantly on action proteins that modify methylation, including methyltransferases, their associated binding proteins, demethylases. These are crucial regulators, orchestrating methylation regulating enzymes corresponding proteins. orchestration facilitates reading, binding, detection, catalysis sites. Methylation ences development, prolisignificantly influferation, invasion, HCC. Furthermore, modification its regulatory mechanisms activate distinct biological characteristics cancer stem cells, such inducing cancer-like differentiation cells. They also influence tumor microenvironment (TME) HCC, modulate immune responses, affect chemotherapy resistance patients, contribute to progression signaling pathway feedback. Given essential role genetic information, it holds promise potential tool for early detection target improve drug promote apoptosis Keywords: modifying biomarkers,

Language: Английский

Citations

2
Regulatory RNAs: role as scaffolds assembling protein complexes and their epigenetic deregulation DOI Creative Commons
Palmiro Poltronieri

Exploration of Targeted Anti-tumor Therapy, Journal Year: 2024, Volume and Issue: 5(4), P. 841 - 876

Published: July 22, 2024

Recently, new data have been added to the interaction between non-coding RNAs (ncRNAs) and epigenetic machinery. Epigenetics includes enzymes involved in DNA methylation, histone modifications, RNA mechanisms underlying chromatin structure, repressive states, active states operating transcription. The main focus is on long ncRNAs (lncRNAs) acting as scaffolds assemble protein complexes. This review does not cover RNA's role sponging microRNAs, or decoy functions. Several lncRNAs were shown regulate activation repression by interacting with Polycomb complexes mixed-lineage leukemia (MLL) activating Various groups reported enhancer of zeste homolog 2 (EZH2) interactions regulatory RNAs. Knowledge function these opens perspective develop therapeutics for cancer treatment. Lastly, interplay epitranscriptomic modifications cancers paves way targets therapy. approach inhibit epitrascriptomics-regulated may bring compounds therapeuticals various types cancer.

Language: Английский

Citations

1
m6A-Methylated NUTM2B-AS1 Promotes Hepatocellular Carcinoma Stemness Feature via Epigenetically Activating BMPR1A Transcription DOI Creative Commons
Wenchuan Li,

Min Zeng,

Yuanjia Ning

et al.

Journal of Hepatocellular Carcinoma, Journal Year: 2024, Volume and Issue: Volume 11, P. 2393 - 2411

Published: Dec. 1, 2024

Purpose: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies in world. Oncofetal proteins are optimal diagnostic biomarkers and therapeutic targets for HCC. As abundant modification RNA, N 6 -methyladenosine (m A) has been reported to be involved HCC initiation progression. However, whether m A oncofetal characteristics remains unknown. Methods: Gene expression tissues cells was detected using qPCR. The level methylation determined methylated RNA immunoprecipitation assay. biological roles NUTM2B-AS1 were Cell Counting Kit-8, 5-ethynyl-2'-deoxyuridine incorporation, spheroid formation assays. mechanisms underlying explored (RIP), chromatin isolation by purification (ChIRP), (ChIP), assay transposase-accessible (ATAC). Results: identified as a novel long noncoding that upregulated fetal liver silenced adult tissues. METTL3 METTL16 induce hypermethylation NUTM2B-AS1. levels exhibit characteristics. upregulates increasing transcript stability. A-methylated promotes cell proliferation stemness via epigenetically activating BMPR1A expression. specifically binds promoter. recognized reader YTHDC2, which further H3K4 methyltransferase MLL1. recruits YTHDC2 MLL1 promoter, leading increased H3K4me3 accessibility at Functional rescue assays suggest critical mediator oncogenic role Conclusion: METTL3- METTL16-mediated molecular event transcription. Keywords: -methyladenosine, molecule, hepatocellular carcinoma, stemness, histone

Language: Английский

Citations

0